Literature DB >> 16505319

PCV chemotherapy for recurrent glioblastoma.

F Schmidt1, J Fischer, U Herrlinger, K Dietz, J Dichgans, M Weller.   

Abstract

The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16505319     DOI： 10.1212/01.wnl.0000197792.73656.c2

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  32 in total

1.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 2.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

3.  Impact of imaging measurements on response assessment in glioblastoma clinical trials.

Authors:  David A Reardon; Karla V Ballman; Jan C Buckner; Susan M Chang; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

4.  An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.

Authors:  Peiman Haddad; Sohrab Shazadi; Farhad Samiei; Homayoun Hadizadeh Kharrazi; Morteza Tabatabaeefar; Afshin Rakhsha; Mohammad Faranoosh; Mohammad Torabi-Nami; Ali Dadras; Atieh Liaghi; Leila Nafarieh
Journal:  Int J Clin Exp Med       Date:  2015-03-15

5.  Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Authors:  Michael Back; Cecelia E Gzell; Marina Kastelan; Linxin Guo; Helen R Wheeler
Journal:  Neurooncol Pract       Date:  2014-12-15

6.  Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.

Authors:  Florian Stockhammer; Martin Misch; Arend Koch; Marcus Czabanka; Michail Plotkin; Cristiane Blechschmidt; Jochen Tuettenberg; Peter Vajkoczy
Journal:  J Neurooncol       Date:  2010-05-06       Impact factor: 4.130

7.  Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.

Authors:  Jan Kuhnhenn; Thomas Kowalski; Sabine Steenken; Kathrin Ostermann; Uwe Schlegel
Journal:  J Neurooncol       Date:  2012-06-29       Impact factor: 4.130

Review 8.  Treating recurrent glioblastoma: an update.

Authors:  Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal:  CNS Oncol       Date:  2015

9.  ACNU-based chemotherapy for recurrent glioma in the temozolomide era.

Authors:  Caroline Happold; Patrick Roth; Wolfgang Wick; Joachim P Steinbach; Michael Linnebank; Michael Weller; Günter Eisele
Journal:  J Neurooncol       Date:  2008-11-06       Impact factor: 4.130

10.  Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.

Authors:  Antonio Silvani; Paola Gaviani; Anna Fiumani; Vidmer Scaioli; Elena Lamperti; Marica Eoli; Andrea Botturi; Andrea Salmaggi
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.